OncoMatch/Clinical Trials/NCT06934044
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Is NCT06934044 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Cevostamab and Tocilizumab for multiple myeloma.
Treatment: Cevostamab · Tocilizumab — This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cevostamab or another agent with the same target
Prior treatment with cevostamab or another agent with the same target
Cannot have received: monoclonal antibody
Exception: except for the use of non-myeloma therapy
Prior use of any monoclonal antibody (mAb), radioimmunoconjugate, or ADC as anti-cancer therapy within 4 weeks before first study treatment, except for the use of non-myeloma therapy
Cannot have received: systemic immunotherapeutic agents
Prior treatment with systemic immunotherapeutic agents, including but not limited to, cytokine therapy and anti-CTLA-4, anti-PD-1, and anti-PD-L1
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T cell therapy within 12 weeks before first cevostamab infusion
Cannot have received: radiotherapy
Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment
Cannot have received: chemotherapeutic agent
Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment
Cannot have received: anti-cancer agent
Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other anti-cancer agent within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first study treatment
Cannot have received: autologous stem cell transplantation
Autologous stem cell transplantation (SCT) within 100 days prior to first study treatment
Cannot have received: allogeneic stem cell transplantation
Prior allogeneic SCT
Cannot have received: solid organ transplantation
Prior solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06934044 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cevostamab or another agent with the same target, monoclonal antibody, systemic immunotherapeutic agents disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages